Improving Quality and Reducing Costs in Schizophrenia Care with New Technologies and New Personnel



Center for Medicaid/Medicare Innovation (CMMI) Grant


08/01/12 – 07/31/15

Contact: Jennifer Gottlieb


The goal of this project is to improve illness management and the overall process of care in treating schizophrenia in order to reduce ER visits and hospital days while providing better care and better health. This will be done by fostering innovation in the use of technology and by training and deploying Mental Health/Health Technology (MH/HT) Case Managers, at 10 community mental health agencies around the country.

The components of the treatment model include: 1) evidence-based pharmacological treatment facilitated by a web-based prescriber decision support system-Prescriber Decision Assistant (PDA) 2) brief, in-person, relapse prevention counseling with supplemental web-based learning modules, 3) Technology to Extend Care and Support to Schizophrenia (TECSS), a program that offers web- and phone-based resources to support persons with schizophrenia and their family members or others. The resources include a patient and family Psycho-Education Treatment program, which includes electronic peer groups facilitated by mental health professionals, providing medication reminders via web and phone, and conducting monitoring of early warning signs of relapse via web and phone 4) an interactive smart phone application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia and 5) a web-based, self-administered cognitive-behavioral therapy (CBT) program for the management of auditory hallucinations and paranoia. 6) Medication sensor technology to monitor adherence will be utilized in a subset of patients. All participants will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and the smart phone application. The other program components will be provided to patients using a shared decision-making approach to assess need and preference.

Our target population is persons between the ages of 18 and 50 with a diagnosis of schizophrenia or schizoaffective disorder who have a history of two or more prior hospitalizations, with at least one having occurred in the previous year and who are currently enrolled in (or eligible for) a Medicaid program or are uninsured. Such individuals have been shown to be at high risk for rehospitalization and high costs of care. This project will have a 3 year total duration, with participants receiving active treatment for a period of 6 months, and has the potential to substantially increase access to treatment and the quality of care for persons with schizophrenia.

BU Center for Psychiatric Rehabilitation Staff Role
Jennifer Gottlieb, Ph.D. Site Principal Investigator
Kim T. Mueser, Ph.D. Co-Investigator
Susan Gingerich, MSW, Independent Consultant Co-Investigator
Vasudha Gidugu, M.A. BU Project Coordinator
Mihoko Maru, M.A. BU Project Coordinator

Other Study StaffInstitutionRole

John Kane, M.D. Feinstein Institute, NY Principal Investigator
Delbert Robinson, M.D. Feinstein Institute, NY Co-Invesigator
Nina Schooler, Ph.D. Feinstein Institute, NY Co-Invesigator
Jim Robinson, M.Ed. Feinstein Institute, NY Co-Invesigator
Patricia Marcy, B.S.N. Feinstein Institute, NY Project Coordinator
Mary Brunette, M.D. Dartmouth Medical School, NH Site PI
Dror Ben-Zeev, Ph.D. Dartmouth Medical School, NH Co-Invesigator
Armando Rotondi, Ph.D. University of Pittsburgh, PA Co-Invesigator
Piper Meyer, Ph.D. University of North Carolina, Chapel Hill Co-Invesigator
Robert Rosenheck, M.D. Yale Medical School, CT Co-Invesigator


No documents are available at this time. Please use the project contact for specific inquiries.


Inquiries related to the project should be addressed to:

Jennifer Gottlieb
Boston University, Center for Psychiatric Rehabilitation
940 Commonwealth Avenue West, 2nd Floor
Boston, MA 02215